Drug Trial Radar · NCT01507922
Comparative Efficacy and Safety of Fenoverine
Last checked: Nov 20, 2026Latest source record: Dec 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Planned (sponsor's estimate)
Start
Dec 2011
Primary completion
Mar 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Bukwang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a randomized double-blind parallel phase IV study to compare Fenoverine and Trimebutine maleate in the efficacy and safety. Study Hypothesis: Fenoverine is non-inferior to Trimebutine maleate in its efficacy and safety.
Conditions
- Irritable Bowel Syndrome
Interventions
FenoverineDrug
Fenoverine 100mg three times a day for 8 weeks
TimebutineDrug
Timebutine maleate 150mg three times a day for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- the proportion of subjects with improvement in abdominal pain or discomfortTime frame: week 8
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Korea University Ansan Hospital
Ansan, South Korea
Hallym University Sacred Heart Hospital
Anyang, South Korea
Kangwon National University Hospital
Chuncheon, South Korea
Gachon University Gil Hospital
Incheon, South Korea
Inje University Seoul Paik Hospital
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.